National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Formoterol fumarate dihydrate, glycopyrronium, budesonide (Trixeo Aerosphere®). HTA ID: 21015

Trixeo Aerosphere® is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 06/04/2021
Rapid review completed 30/04/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that for/gly/bud (Trixeo Aerosphere ®) be considered for reimbursement*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement  September 2021.